Herpes simplex type-1 virus infection

Quintessence International

Volumn 34, Issue 6, 2003, Pages 453-467

  Huber, Michaell A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 UNDECENOIC ACID; ACICLOVIR; ANTIVIRUS AGENT; ASCORBIC ACID; BEHENYL ALCOHOL; FAMCICLOVIR; FOSCARNET; LITHIUM CARBONATE; LYSINE; PENCICLOVIR; POVIDONE IODINE; TETRACAINE; VALACICLOVIR;

CLINICAL FEATURE; DENTISTRY; DIAPHORESIS; DIARRHEA; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; ELECTROLYTE DISTURBANCE; FEVER; HEADACHE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HYDRATION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; LATENT PERIOD; MORBIDITY; MORTALITY; MOUTH HYGIENE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; RASH; RECURRENT DISEASE; REVIEW; SEIZURE; STOMATITIS; VERTIGO; VOMITING; HERPES LABIALIS; PATHOGENICITY; PATHOLOGY; VIROLOGY; VIRUS LATENCY;

ANTIVIRAL AGENTS; HERPES LABIALIS; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; RECURRENCE; STOMATITIS, HERPETIC; VIRUS LATENCY;

EID: 0141505920     PISSN: 00336572     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Oakley C, Epstein JB, Sherlock CH. Reactivation of herpes simplex virus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:272-278.
2. Stewart JA, Reef SE, Peliett PE, Corey L, Whitley RJ. Herpes virus infections in persons infected with human immunodeficiency virus. Clin Infec Dis 1995;21(suppl 1):S114-S120.
3. Greenberg MS. Herpes virus infections. Dent Clin North Am 1996;40:359-368.
4. Corey L, Spear PG. Infections with herpes simplex viruses (First of two parts). N Engl J Med 1986;314:686-691.
5. Eversole LR. Inflammatory diseases of the mucous membranes. Part 1. Viral and fungal infections. J Calif Dent Assoc 1994;22:52-57.
6. Miller CS, Danaher RJ, Jacob RJ. Molecular aspects of herpes simplex virus 1 latency, reactivation, and recurrence. Crit Rev Oral Biol Med 1998;9:541-562.
7. Riley LE. Herpes simplex virus. Semin Perinatol 1998;22:284-292.
8. Corey L. First-episode, recurrent, and asymptomatic herpes simplex infections. J Am Acad Dermatol 1998;18:169-172.
9. Epstein JB, Sherlock C, Page JL, Spinelli J, Phillips G. Clinical study of herpes simplex virus infection in leukemia. Oral Surg Oral Med Oral Pathol 1990;70:38-43.
10. Vestey JP, Nroval M. Mucocutaneous infections with herpes simplex virus and their management. Clin Exp Dermatol 1992;17:221-237.
11. Spruance SL, Freeman DJ, Stewart JCB, et al. The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. J Infect Dis 1991;163:728-734.
12. Merchant VA, Molinari JA, Sabes WR. Herpetic whitlow: Report of a case with multiple recurrences. Oral Surg Oral Med Oral Pathol 1983;55:568-571.
13. Mertz GJ, Critchlow CW, Benedetti J, et al. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex infection. J Am Med Assoc 1984;252:1147-1151.
14. Mindel A, Weller IVD, Faherty A, Sutherland S, Fiddian AP, Adler MW. Acyclovir in first attacks of genital herpes and prevention of recurrences. Genitourin Med 1986;62:28-32.
15. Meyers JD. Treatment of herpes virus infections in the immunocompromised host. Scand J Infect Dis Suppl 1985;47:128-136.
16. Wutzler P. Antiviral therapy of herpes simplex and varicellazoster virus infections. Intervirology 1997;40:343-356.
17. Scott DA, Coulter WA, Biagioni PA, O'Neill HO, Lamey PJ. Detection of herpes simplex virus type 1 shedding in the oral cavity by polymerase chain reaction and enzyme-linked immunosorbent assay at the prodromal stage of recrudescent herpes labialis. J Oral Pathol Med 1997;26:305-309.
18. Scott DA, Coulter WA, Lamey PJ. Oral shedding of herpes simplex virus type 1: A review. J Oral Pathol Med 1997;26:441-447.
19. Rooney JF, Bryson Y, Mannix ML, et al. Prevention of ultraviolet-light-induced herpes labialis by sunscreen. Lancet 1991;338:1419-1422.
20. Padgett DA, Sheridan JF, Dorne J, Berntson GG, Candelora J, Glaser R. Social stress and the reactivation of latent herpes simplex virus type 1. Proc Natl Acad Sci USA 1998;95:7231-7235.
21. Dalkvist J, Robins TB, Wahlin R, Bartsch E, Forsbeck M. Herpes simplex and mood: A prospective study. Psychosom Med 1995;57:127-137.
22. Bales JF. Viral encephalitis. Med Clin North Am 1993;77:25-42.
23. Christie SN, McCaughey C, Marley JJ, Coyle PV, Scott DA, Lamey PJ. Recrudescent herpes simplex infection mimicking primary herpetic gingivostomatitis. J Oral Pathol Med 1998;27:8-10.
24. Siegel MA. Strategies for management of commonly encountered oral mucosal disorders. J Calif Dent Assoc 1999;27:210-212,215,218-219.
25. Gold D, Corey L. Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother 1987;31:361-367.
26. Lycke E. Virological aspects of herpes virus infections. Scand Infect Dis 1985;(suppl 47):9-15.
27. Eversole LR. Viral infections of the head and neck among HIV-seropositive patients. Oral Surg Oral Med Oral Pathol 1992;73:155-163.
28. Eisen D, Essell J, Broun ER. Oral cavity complications of bone marrow transplantation. Semin Cutan Med Surg 1997;16:265-272.
29. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981;305:63-67.
30. Terezhalmy GT, Bottomley WK, Pelleu GB. The use of water-soluble bioflavanoid-ascorbic acid complex in the treatment of recurrent herpes labialis. Oral Surg Oral Med Oral Pathol 1978;45:56-62.
31. Hicks ML, Terezhalmy GT. Herpes virus hominis type 1: A summary of structure, composition, growth cycle, and cytopathogenic effects. Oral Surg Oral Med Oral Pathol 1979;48:311-318.
32. Corey L, Spear PG. Infections with herpes simplex viruses (Second of two parts). N Engl J Med 1986;314:749-757.
33. Emmert DH. Treatment of common cutaneous herpes simplex virus infections. Am Faro Physician 2000;61:1697-1704,1705-1706,1708.
34. Hijikata Y, Tsukamoto Y. Effect of herbal therapy on herpes labialis and herpes genitalis. Biotherapy 1998;11:235-240.
35. Simmons A. An open-label study conducted to evaluate the efficacy of Betadine cold sore paint. Dermatology 1997;195(suppl 2):85-88.
36. Woo SB, Fu-Keung Lee S. Oral recrudescent herpes simplex virus infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:239-243.
37. Kesson A. Use of aciclovir in herpes simplex virus infections. J Paediatr Child Health 1998;34:9-13.
38. Glick M, Goldman H. Viral infections in the dental setting: Potential effects on pregnant HCWs. J Am Dent Assoc 1993;124:79-85.
39. Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: A randomised double blind placebo controlled study. BMJ 1997;314:1800-1803.
40. Laskaris G. Oral manifestations of infectious diseases. Dent Clin North Am 1996;40:395-423.
41. Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982;73:229-235.
42. Stanberry LR, Floyd-Reising SA, Connelly BL, Alter SJ, Gilchrist MJR, Rubino C, Myers MG. Herpes simplex viremia: Report of eight pediatric cases and review of the literature. Clin Infect Dis 1994;18:401-407.
43. Wade JC, McLaren C, Meyers JD. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 1983;148:1077-1082.
44. Reichart PA. Oral ulcerations in HIV infection. Oral Dis 1997;3(suppl 1):S180-S182.
45. Heimdahl A. Prevention and management of oral infections in cancer patients. Support Care Cancer 1999;7:224-228.
46. Itin PH, Lautenschlager S. Viral lesions of the mouth in HIV-infected patients. Dermatology 1997;194:1-7.
47. Lundgren G, Wilczek H, Lonnqvist B, Lindholm A, Wahren B, Ringden O. Acyclovir prophylaxis in bone marrow transplant patients. Scand J Infect Dis Suppl 1985;47:137-144.
48. Nahata MC. Clinical use of antiviral drugs. Drug Intell Clin Pharm 1987;21:399-405.
49. Keating MR. Antiviral agents for non-human immunodeficiency virus infections. Mayo Clin Proc 1999;74:1266-1283.
50. Redding SW, Montgomery MT. Acyclovir prophylaxis for oral herpes simplex virus infection in patients with bone marrow transplants. Oral Surg Oral Med Oral Pathol 1989;67:680-683.
51. Scully C, Laskaris G, Pindborg J, Porter SR, Reichart P. Oral manifestations of HIV infection and their management. I. More common lesions. Oral Surg Oral Med Oral Pathol 1991;71:158-166.
52. Cohen S, Williamson GM. Stress and infectious disease in humans. Psychol Bul 1991;109:5-24.
53. Logan HL, Lutgendorf S, Hartwig A, Lilly J, Berberich SL. Immune, stress and mood markers related to recurrent oral herpes outbreaks. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:48-54.
54. Nahass GT, Goldstein BA, Zhu WY, Serfling U, Penneys NS, Leonardi CL. Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection. J Am Med Assoc 1992;268:2541-2544.
55. Patton LL, van der Horst C. Oral infections and other manifestations of HIV disease. Infect Dis Clin North Am 1999;13:879-900.
56. Ramos-Gomez FJ, Flaitz C, Catapano P, Murray P, Milnes AR, Dorenbaum A. Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HIV-infected pediatric patients. J Clin Pediatr Dent 1999;23:85-96.
57. Terezhalmy GT, Tyler MT, Ross GR. Eczema herpeticum: Atopic dermatitis complicated by primary herpetic gingivostomatitis. Oral Surg Oral Med Oral Pathol 1979;48:513-516.
58. Robayna MG, Harranz P, Rubio FA, Pena JM, Gonzales J, Casado M. Destructive herpetic whitlow in AIDS: Report of three cases. Br J Dermatol 1997;137:812-815.
59. Brice SL, Krzemien D, Weston WL, Huff JC. Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme. J Invest Dermatol 1989;93:183-187.
60. Lemak MA, Duvic M, Bean SF. Oral acyclovir for the prevention of herpes-associated erythema multiforme. J Am Acad Dermatol 1986;15:50-54.
61. Katz J, Livneh A, Shemer J, Danon YL, Peretz B. Herpes simplex-associated erythema multiforme (HAEM): A clinical therapeutic dilemma. Pediatr Dent 1999;21:359-362.
62. Noone J, Longe S. Bell's palsy in the primary care setting: A case study. Clin Excell Nurse Pract 1998;2:206-211.
63. Ashenburg C, Rothstein FC, Dahms BB. Herpes esophagitis in the immunocompetent child. J Pediatr 1986;108:584-587.
64. Matsumoto J, Sumiyoshi A. Herpes simplex esophagitis-A study in autopsy series. Am J Clin Pathol 1985;84:96-99.
65. Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation. Ann Intern Med 1982;96:265-269.
66. Raborn GW, Martel AY, Grace MGA, McGaw WT. Oral acyclovir in prevention of herpes labialis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:55-59.
67. Mindel A. Is it meaningful to treat patients with recurrent herpetic infections? Scand J Infect Dis Suppl 1991;80:27-32.
68. Raborn GW, McGaw WT, Grace M, Percy J. Treatment of herpes labialis with acyclovir. Review of three clinical trials. Am J Med 1988;85:39-42.
69. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: Results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother 2002;46:2238-2243.
70. Spruance SL, Rowe NH, Rayborn GW, Thibodeau EA, D'Ambrosio JA Bernstein DI. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. J Infect Dis 1999;179:303-310.
71. Siegel MA, Silverman S Jr, Sollecito TP (eds). Clinician's Guide to Treatment of Common Oral Lesions, ed 5. Baltimore: American Academy of Oral Medicine, 2001.
72. Hess GP, Watson PD. Seizures secondary to oral viscous lidocaine. Ann Emerg Med 1988;17:725-727.
73. Wagstaff AJ, Faulds D, Goa KL. Aciclovir-A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:153-205.
74. Hamuy R, Berman B. Treatment of herpes simplex virus infections with topical antiviral agents. Eur J Dermatol 1998;8:310-319.
75. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook, ed 10. Hudson, OH: Lexi-Comp, 2002.
76. Westheim AI, Tenser RB, Marks JG. Acyclovir resistance in a patient with chronic mucocutaneous herpes simplex infection. J Am Acad Dermatol 1987;17:875-880.
77. Erlich KS, Mills J, Chatis P, Mertz GJ, Busch DF, Follansbee SE, Grant RM, Crumpacker CS. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989;320:293-296.
78. Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989;320:297-300.
79. Iino T, Gondo H, Ohno Y, et al. Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation. Bone Marrow Transplant 1996;18:1185-1188.
80. Alrabiah FA, Sacks SL. New antiherpes virus agents, their targets and therapeutic potential. Drugs 1996;52:17-32.
81. Sacks SL, Wilson B. Famciclovir/penciclovir. Adv Exp Med Biol 1999;458:135-147.
82. Lazarus HM, Belanger R, Candoni A, et al. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: Results of a multicenter, acyclovir-controlled trial. Antimicrob Agents Chemother 1999;43:1192-1197.
83. Spruance SL, Rowe NH, Raborn GW, Thibodeau EA, D'Ambrosio JA, Bernstein DI. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo controlled, multicenter trial. J Infect Dis 1999;179:303-310.
84. Boon R, Goodman JJ, Martinez J, Marks GL, Gamble M, Welch C. Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: A randomized, double-blind, placebo-controlled trial. Penciclovir cream herpes labialis study group. Clin Ther 2000;22:76-90.
85. Abramowicz M. Valvcyclovir (valtrex) for herpes labialis. Med Lett Drugs Ther 2002;44:95-98.
86. Sande MA, Armstrong D, Corey L, et al. Perspectives on switching oral acyclovir from prescription to over-the-counter status: Report of a consensus panel. Clin Infect Dis 1998;26:659-663.
87. Sacks SL, Thisted RA, Jones TM, et al. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol 2001;45:222-230.
88. Spruance SL. N-docosanol (Abreva) for herpes labialis: Problems and questions. J Am Acad Dermatol 2002;47:457-458.
89. Hovi T, Hirvimies A, Stenvik M, Vuola E, Pippuri R. Topical treatment of recurrent mucocutaneous herpes with ascorbic acid-containing solution. Antiviral Res 1995;27:263-270.
90. Wright EF. Clinical effectiveness of lysine in treating recurrent aphthous ulcers and herpes labialis. Gen Dent 1994;42:40-42.
91. Bschor T. Complete suppression of recurrent herpes labialis with lithium carbonate. Pharmacopsychiatry 1999;32:158.
92. Bernstein DI, Schleupner CJ, Evans TG, et al. Effect of foscarnet cream on experimental UV radiation-induced herpes labialis. Antimicrob Agents Chemother 1997;41:1961-1964.
93. Shafran SD, Sacks SL, Aoki FY, et al. Topical undecylenic acid for herpes simplex labialis: A multicenter, placebo-controlled trial. J Infect Dis 1997;176:78-83.
94. Koytchev R, Alken RG, Dundarov S. Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis. Phytomedicine 1999;6:225-230.
95. Karadi I, Karpati S, Romics L. Aspirin in the management of recurrent herpes simplex virus infection. Ann Intern Med 1998;128:696-697.
96. Kaminester LH, Pariser RJ, Pariser DM, et al. A double-blind, placebo-controlled study of topical tetracaine in the treatment of herpes labialis. J Am Acad Dermatol 1999;41:996-1001.
97. Whitley RJ, Levin M, Burton N, et al. Infections caused by herpes simplex virus in the immunocompromised host: Natural history and topical acyclovir therapy. J Infect Dis 1984;150:323-329.